Maharashtra FDA issues 'stop production orders' to 16 pharma units for norm violations

Representative Image

Maharashtra's Food and Drug Administration (FDA) on Tuesday said it has issued "stop production orders" to as many as 16 pharmaceutical units for serious violations of norms, an action which comes after the regulator carried out inspection of 655 pharma manufacturing facilities in the last three months in the state.

An official release issued by the FDA said the state agency enforces the Drugs and Cosmetics Act, 1940 and Rules, 1945, and as part of its mandate carries out regular inspection of entities covered under the legislation. The law regulates the production and sale of medicines and cosmetics in the state.

Pharmaceutical manufacturers are required to produce quality medicines in accordance with the Good Manufacturing Practices as prescribed under Schedule M of the Drugs and Cosmetics Rules, the release said. A verification and inspection programme covering the pharma manufacturing units in the state was carried out by the FDA between January 2022 and March 2022, the release said.

During this period, facilities of 655 manufacturers were inspected in the state and show-cause notices were issued to 95 entities for non-compliance of provisions, the FDA said. As many as 16 manufacturing units have been issued "stop production orders" for serious violations of norms and 17 others served notices for submission of compliance reports, the release said.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever